These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53. Hepagene (PowderJect). Jones T Curr Opin Investig Drugs; 2002 Jul; 3(7):987-91. PubMed ID: 12186276 [TBL] [Abstract][Full Text] [Related]
54. Repifermin. Human Genome Sciences/GlaxoSmithKline. Wheeler G IDrugs; 2001 Jul; 4(7):813-9. PubMed ID: 15995938 [TBL] [Abstract][Full Text] [Related]
55. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
56. A forensic evaluation of the National Emphysema Treatment Trial using the expected value of information approach. Ramsey SD; Blough DK; Sullivan SD Med Care; 2008 May; 46(5):542-8. PubMed ID: 18438203 [TBL] [Abstract][Full Text] [Related]
57. The market for antituberculosis drugs and vaccines: incentives for investment in new products. Chaudhry RG; Bishai DM Expert Rev Pharmacoecon Outcomes Res; 2005 Dec; 5(6):775-81. PubMed ID: 19807619 [TBL] [Abstract][Full Text] [Related]
59. FR209602 and related compounds, novel antifungal lipopeptides from coleophoma crateriformis no. 738. II. In vitro and in vivo antifungal activity. Kanasaki R; Abe F; Furukawa S; Yoshikawa K; Fujie A; Hino M; Hashimoto S; Hori Y J Antibiot (Tokyo); 2006 Mar; 59(3):145-8. PubMed ID: 16724454 [TBL] [Abstract][Full Text] [Related]
60. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Gupta K; Miller JD; Li JZ; Russell MW; Charbonneau C Cancer Treat Rev; 2008 May; 34(3):193-205. PubMed ID: 18313224 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]